Literature DB >> 28616288

Decreased expression of perforin in CD8+ T lymphocytes in patients with Mycobacterium tuberculosis infection and its potential value as a marker for efficacy of treatment.

Hongbin Jiang1, Huili Gong2, Qing Zhang3, Jin Gu3, Li Liang3, Jun Zhang4.   

Abstract

BACKGROUND: Cytolytic activity against mycobacteria tuberculosis (MTB) within the infected macrophage is a crucial step in the immunity against TB infection, as MTB is an intracellular bacterium. Cytotoxic molecules such as perforin and granzymes produced by cytolytic T cells directly participate in this process. In this study, we evaluated the cytotoxicity function employing flow cytometry analysis of the level of expression of interferon-γ (IFN-γ), perforin and granzyme B in CD8+ T cells from patients with active pulmonary TB (PTB), stable PTB and healthy controls, and explored whether MTB antigen (MTB Ag)-stimulated cytotoxic molecules would be useful for monitoring responses to anti-TB treatment.
METHODS: Intracellular IFN-γ, perforin, and granzyme B were measured by flow cytometry in CD8+ T lymphocyte populations from peripheral blood mononuclear cells before and after stimulation with ESAT-6 and CFP-10 peptides for 72 hours. A total of 38 healthy controls, 52 PTB patients after treatment for 2 months and 58 patients with active PTB were enrolled.
RESULTS: The positive rate of IFN-γ+ CD8+ T cells was expressed higher in active PTB patients and stable PTB compared to healthy controls. Expression of perforin in CD8+ T lymphocytes was lower in the active PTB than the stable PTB. Positive downregulation of perforin and granzyme B after stimulation with ESAT-6 and CFP-10 peptides in active PTB and stable PTB was seen. IFN-γ was upregulated after stimulation. ROC curve analysis showed that the area under the curve (AUC) of perforin and perforin + IFN-γ after stimulation were 0.766 (P=0.000), 0.802 (P=0.000), respectively.
CONCLUSIONS: Our results show that expression of perforin in CD8+ T lymphocytes is downregulated in PTB infection and ESAT-6 and CFP-10 peptides might participate in the downregulation process. This finding cautiously suggests that MTB Ag-stimulated perforin downregulation and IFN-γ upregulation might be a potential index for monitoring therapy response in active PTB patients.

Entities:  

Keywords:  (interferon-γ) IFN-γ; CD8+T lymphocytes; Tuberculosis (TB); granzyme B; perforin

Year:  2017        PMID: 28616288      PMCID: PMC5465152          DOI: 10.21037/jtd.2017.05.74

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  25 in total

1.  Effector functions of heparin-binding hemagglutinin-specific CD8+ T lymphocytes in latent human tuberculosis.

Authors:  Stéphane T Temmerman; Sammy Place; Anne-Sophie Debrie; Camille Locht; Françoise Mascart
Journal:  J Infect Dis       Date:  2005-06-09       Impact factor: 5.226

Review 2.  Controversies in granzyme biology.

Authors:  O Susanto; J A Trapani; D Brasacchio
Journal:  Tissue Antigens       Date:  2012-12

3.  CD4+ T cell-dependent IFN-γ production by CD8+ effector T cells in Mycobacterium tuberculosis infection.

Authors:  Tyler D Bold; Joel D Ernst
Journal:  J Immunol       Date:  2012-07-25       Impact factor: 5.422

4.  Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy.

Authors:  S Brahmbhatt; G F Black; N M Carroll; N Beyers; F Salker; M Kidd; P T Lukey; K Duncan; P van Helden; G Walzl
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

Review 5.  Tuberculosis.

Authors:  Stephen D Lawn; Alimuddin I Zumla
Journal:  Lancet       Date:  2011-03-21       Impact factor: 79.321

6.  Cytotoxicity responses to selected ESAT-6 and CFP-10 peptides in tuberculosis.

Authors:  M Madhan Kumar; Alamelu Raja
Journal:  Cell Immunol       Date:  2010-08-20       Impact factor: 4.868

Review 7.  Nuclear war: the granzyme A-bomb.

Authors:  Judy Lieberman; Zusen Fan
Journal:  Curr Opin Immunol       Date:  2003-10       Impact factor: 7.486

8.  Mycobacterium tuberculosis-specific CD8+ T cells require perforin to kill target cells and provide protection in vivo.

Authors:  Joshua S Woodworth; Ying Wu; Samuel M Behar
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

9.  Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases.

Authors:  Ifedayo M O Adetifa; Martin O C Ota; Brigitte Walther; Abdulrahman S Hammond; Moses D Lugos; David J Jeffries; Simon A Donkor; Richard A Adegbola; Philip C Hill
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

10.  High IL-35 pleural expression in patients with tuberculous pleural effusion.

Authors:  Xuan Dong; Jiong Yang
Journal:  Med Sci Monit       Date:  2015-05-03
View more
  6 in total

1.  Transcriptional Profiling of Early and Late Phases of Bovine Tuberculosis.

Authors:  Hazem F M Abdelaal; Tyler C Thacker; Bishoy Wadie; Mitchell V Palmer; Adel M Talaat
Journal:  Infect Immun       Date:  2021-12-13       Impact factor: 3.609

2.  Changes in T-lymphocyte subsets and risk factors in human immunodeficiency virus-negative patients with active tuberculosis.

Authors:  Kui Li; Renyu Ran; Zicheng Jiang; Chuanqi Fan; Tao Li; Zhiguo Yin
Journal:  Infection       Date:  2020-05-29       Impact factor: 3.553

3.  In-Depth Immunophenotyping With Mass Cytometry During TB Treatment Reveals New T-Cell Subsets Associated With Culture Conversion.

Authors:  Carole Chedid; Thibault Andrieu; Eka Kokhreidze; Nestani Tukvadze; Samanta Biswas; Md Fahim Ather; Mohammad Khaja Mafij Uddin; Sayera Banu; Flavio De Maio; Giovanni Delogu; Hubert Endtz; Delia Goletti; Marc Vocanson; Oana Dumitrescu; Jonathan Hoffmann; Florence Ader
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 8.786

4.  Using TBAg/PHA Ratio for Monitoring TB Treatment: A Prospective Multicenter Study.

Authors:  Xiaochen Wang; Mingwu Li; Guobiao Liu; Xiaoying Wu; Rong Wan; Hongyan Hou; Shiji Wu; Ziyong Sun; Haobin Kuang; Feng Wang
Journal:  J Clin Med       Date:  2022-06-29       Impact factor: 4.964

5.  Opti-4TB: A protocol for a prospective cohort study evaluating the performance of new biomarkers for active tuberculosis outcome prediction.

Authors:  Olivier Bahuaud; Charlotte Genestet; Jonathan Hoffmann; Oana Dumitrescu; Florence Ader
Journal:  Front Med (Lausanne)       Date:  2022-09-14

6.  Gene expression profiles classifying clinical stages of tuberculosis and monitoring treatment responses in Ethiopian HIV-negative and HIV-positive cohorts.

Authors:  Gebremedhin Gebremicael; Desta Kassa; Yodit Alemayehu; Atsbeha Gebreegziaxier; Yonas Kassahun; Debbie van Baarle; Tom H M Ottenhoff; Jacqueline M Cliff; Mariëlle C Haks
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.